Kidney failure

Novel AI-Driven Model Validated to Predict Risk of Chronic Kidney Disease Progression in Large U.S. Study

Retrieved on: 
Saturday, November 4, 2023
Medical Affairs Bureau, Research, Insurance, EGFR, Medicare, Physician, Kidney failure, Glomerular filtration rate, HIV disease progression rates, Society, American Society of Nephrology, Chronic kidney disease, Boehringer Ingelheim, Dialysis, Disease, ASN, Risk, Machine learning, Medicaid, Urinalysis, CKD, Chemistry, Patient, Diagnosis, Ingelheim am Rhein, Cryptocurrency, Pharmaceutical industry, Medical device

Using data from a diverse population of over 4 million U.S. adults, the model was more than 80% accurate in predicting CKD progression over a five-year period.

Key Points: 
  • Using data from a diverse population of over 4 million U.S. adults, the model was more than 80% accurate in predicting CKD progression over a five-year period.
  • These findings were presented in an oral session at the American Society of Nephrology (ASN) Kidney Week conference in Philadelphia, being held from November 1-5, 2023.
  • Physicians need novel tools to evaluate risk of CKD progression, which could assist with earlier diagnosis and treatment."
  • The Klinrisk model was developed to predict the risk of CKD progression, defined as either a 40% decline in estimated glomerular filtration rate (eGFR) or kidney failure (dialysis, kidney transplant or eGFR below 10 mL/min/1.73 m2).

Global Dialysis Market Set for Impressive Growth, Projected to Reach US$107.96 Billion by 2023 with a Strong CAGR of 4.80% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023
Health, Medical Devices, Diabetes, Hospitals, Managed Care, General Health, Biotechnology, Kidney, Waste, Incidence, Kidney failure, Equipment, Prevalence, Co-production (public services), Chronic kidney disease, Dialysis, Growth, COVID-19, Blood, Kidney disease, CKD, ESRD, Safety, Peritoneal dialysis, Video game, Medical device, Patient, Hemodialysis

The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.

Key Points: 
  • The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.
  • The services segment currently holds the largest market share, while consumables are anticipated to exhibit the highest growth with a significant CAGR.
  • By Type: The global dialysis market is segmented into Hemodialysis and Peritoneal Dialysis.
  • The global dialysis market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

DaVita Collaborates with Google Cloud to Develop Customized Clinical Operating System Designed to Transform Kidney Care

Retrieved on: 
Wednesday, October 18, 2023
Cloud, Medical Affairs Bureau, NYSE, BigQuery, Crash, ESKD, Kidney failure, National Kidney Foundation, Organization, Kidney disease, Google Cloud, Chronic kidney disease, DaVita Inc., Dialysis, Caregiver, IA Financial Group, Machine learning, Hospital, CKD, AI, Google Cloud Platform, Patient, Society for Healthcare Strategy and Market Development, Medical device, Pharmaceutical industry, Nursing

SUNNYVALE, Calif., Oct. 18, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) and Google Cloud today announced that the organizations have collaborated to create a new clinical operating system that sets a foundation for streamlined kidney care for more than 200,000 DaVita patients.

Key Points: 
  • Kidney care provider harnesses the power of Google Cloud's leading-edge infrastructure, AI, and analytics tools to help improve care plans and streamline clinical workflows
    SUNNYVALE, Calif., Oct. 18, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) and Google Cloud today announced that the organizations have collaborated to create a new clinical operating system that sets a foundation for streamlined kidney care for more than 200,000 DaVita patients.
  • With the deployment, DaVita has moved from a decentralized clinical documentation system to a unified platform that leverages data from more than 30 million dialysis treatments per year to generate insights designed to help improve clinical outcomes.
  • Ultimately, the platform is designed to support DaVita's mission to provide integrated kidney care that helps, improve patient quality of life, and lower the cost of care.
  • A leader in kidney care, DaVita has more than 20 years of clinical data, based on the more than 30 million dialysis treatments the organization administers each year.

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

Retrieved on: 
Tuesday, October 17, 2023
EGFR, APLS, Biomarker, Inflammation, Columbia University Irving Medical Center, Kidney failure, Society, Week, Columbia University, Recurrence, Disease, Kidney, ASN, Proteinuria, VALIANT, Rare, Adolescence, Poster, Glomerular filtration rate, American Society of Nephrology, Patient, Medical device, Pharmaceutical industry

The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan.

Key Points: 
  • The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan.
  • Five (50%) patients showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline.
  • Excessive deposition of C3 breakdown products in the kidney leads to inflammation and damage of the kidney, often causing kidney failure.
  • Data from the Phase 2 DISCOVERY study investigating pegcetacoplan in patients with C3G in native kidneys was recently published in KI Reports .

Premier Investment Showcase: The 11th Annual Investor Capital Expo in Philadelphia For The First Time Since 2019

Retrieved on: 
Tuesday, October 10, 2023
Capital, Keiretsu Forum, Investment, Infection, DART, Angel Capital Association, Humanetics, CST, Venture capital, Bacteria, Communication, Therapy, Kidney failure, Safety, Otitis, Fungus, GPCR, Cancer, G protein-coupled receptor, FDA, Cira Centre, Virus, Orthopedic surgery, Chairperson, Biotechnology, Mount Carmel East, Research, Mentorship, Financial services, Dentistry, Expo

Over 200 accredited angel investors from the Keiretsu Forum Mid-Atlantic and South-East are coming together for the 11th Annual Investor Capital Expo .

Key Points: 
  • Over 200 accredited angel investors from the Keiretsu Forum Mid-Atlantic and South-East are coming together for the 11th Annual Investor Capital Expo .
  • Twelve carefully screened early-stage entrepreneurs will pitch investors on October 25, 2023, at CYTO | Philly in the Cira Center.
  • Each presenting company is actively funding and has a complete Due Diligence Report and Investment Package.
  • The Investor Capital Expo provides a unique format for investors and breakthrough startups to learn, network, collaborate and forge relationships.

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Retrieved on: 
Tuesday, October 10, 2023
Annual general meeting, Calcium, Partnership, Walking, Cancer, Urine, Hypocalcemia, Research, PTH, The New England Journal of Medicine, Standard of care, Kidney failure, Society, American Society for Bone and Mineral Research, National Institute of Dental and Craniofacial Research, Vitamin D, Craniofacial, Kidney, Parathyroid hormone, Hypercalciuria, Hypercalcaemia, Bangladesh Technical Education Board, Blood, Endocrine Society, Patient, Quality of life, NIH, PALO, Pharmaceutical industry, Dietary supplement

“Conventional therapy for ADH1 includes raising the blood calcium levels with calcium supplements and activated vitamin D, taken in multiple doses throughout day.

Key Points: 
  • “Conventional therapy for ADH1 includes raising the blood calcium levels with calcium supplements and activated vitamin D, taken in multiple doses throughout day.
  • But this burdensome regimen may also increase urine calcium levels above normal, which can damage the kidney, leading to kidney failure in worst-case scenarios.
  • People with ADH1 need better treatments, so they are not constantly walking on a tightrope.
  • As part of the Phase 2b study, participants completed one or two 5-day inpatient dose-ranging periods, followed by a 24-week outpatient period.

Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout

Retrieved on: 
Monday, October 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Incidence, Probability, Urine, Mass balance, Inflammation, Gout, Aes, Benzbromarone, Liver, Kidney failure, IND, Safety, SUA, Disease, Atom, DSM-IV codes, Chugai Pharmaceutical Co., CNY, Hyperuricemia, URAT1, Patient, Quality of life, Pharmaceutical industry, Dietary supplement

After this round of financing, Atom has raised a total of nearly $165 million.

Key Points: 
  • After this round of financing, Atom has raised a total of nearly $165 million.
  • "We appreciate the support of every investment institution involved in the D-round financing and previous investors,” said Dr. William Dongfang Shi, CEO, Chairman and Founder of Atom Bioscience.
  • Maintaining sUA levels of 5 mg/dL to 4 mg/dL in gout patients is recommended by many national gout treatment guidelines.
  • At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced.

Hemodialysis Dominates the Global Dialysis Market with Advanced Technology and Widespread Availability - ResearchAndMarkets.com

Retrieved on: 
Friday, October 13, 2023
Medical Devices, Health, Diabetes, Hospitals, Managed Care, Biotechnology, Dialysis, Kidney disease, Hospital, Hypertension, Investment, Chronic kidney disease, Research, ESRD, Prevalence, Risk, CKD, Creatinine, Kidney failure, Insurance, Ageing, Urea, Patient, Kidney transplantation, Blood, Waste, Pharmaceutical industry, Medical device, Growth

The global dialysis market is set to achieve remarkable growth, projected to exceed $141.26 billion by 2028, according to Renub Research.

Key Points: 
  • The global dialysis market is set to achieve remarkable growth, projected to exceed $141.26 billion by 2028, according to Renub Research.
  • Chronic kidney disease (CKD) is a progressive condition affecting over 10% of the global population, totaling more than 800 million individuals.
  • The global prevalence of diabetes among people aged 20-79 was 11% in 2021, expected to rise to 12% by 2045.
  • Additionally, Chinese companies have made significant strides in manufacturing dialysis equipment, contributing to both domestic supply and global export.

Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout

Retrieved on: 
Monday, October 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, SUA, Probability, Urine, DSM-IV codes, Liver, Kidney failure, Chugai Pharmaceutical Co., Safety, Inflammatory arthritis, Hyperuricemia, URAT1, Gout, Patient, Part, Pharmaceutical industry

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout.
  • Part 2 of the study will be a confirmatory study for dosing regimens of ABP-671 selected from Part 1.
  • “Gout affects more than 50 million people worldwide and is on the rise in many countries,” said Atom Bioscience CEO, Chairman and Founder Dr. William Dongfang Shi.
  • At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced.

Nearly 60% of Native Americans Living with Type 2 Diabetes Face Serious, Costly Behavioral Health Challenges

Retrieved on: 
Thursday, October 5, 2023
Diabetes, General Health, Health Technology, Health, Type 2 diabetes, Incidence, Native, Obesity, Moyamoya disease, Anxiety, LEA, Amputation, Homelessness, Risk, PAD, Kidney failure, Mortality, Transport, Ageing, Health status of Asian Americans, Native Americans, Depression, White Americans, RPM, Patient, Pharmaceutical industry, Nursing

For example, 57% of those surveyed report that in addition to type 2 diabetes, they are also living with a chronic behavioral health condition.

Key Points: 
  • For example, 57% of those surveyed report that in addition to type 2 diabetes, they are also living with a chronic behavioral health condition.
  • Native Americans living with type 2 diabetes are also facing myriad mounting challenges when it comes to managing and maintaining their personal health and well-being.
  • The survey found that nearly half (45%) of Native Americans living with type 2 diabetes believe it’s harder to access high-quality care compared to other races and ethnicities.
  • The Podimetrics survey found broad support for inclusion of clinical support with RPM technology among Native Americans with type 2 diabetes.